Drugs / Emtricitabine/Tenofovir Alafenamide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04661397 | Jan → Jul 2021 | — | Janssen Research & Development, LLC | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-10-25 | Janssen Research & Development, LLC | Results Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial jnj.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-10-25 | Janssen Research & Development, LLC | Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial jnj.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/Tenofovir Alafenamide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04661397 ↗ |
| Known as | F/TAF | “Darunavir (DRV), Emtricitabine/Tenofovir Alafenamide (F/TAF) and Cobicistat (COBI) tablet under fed condition on Day 1” NCT04661397 ↗ |
| Route | Oral | “Participants will receive a single dose of Emtricitabine/Tenofovir Alafenamide tablet orally as per assigned treatment sequence.” NCT04661397 ↗ |